D. L. Kerr

CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer

This study shows that CDK4/6 upregulation causes DNA replication stress and genomic instability, leading to resistance to EGFR inhibitors in lung cancer, and suggests combining CDK4/6 and EGFR inhibitors as a treatment.

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

This study identifies a FAK-YAP signaling axis that drives drug-tolerant persister cells and residual disease in lung cancer, showing that inhibiting this axis improves tumor response to targeted therapies.

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

This study shows that targeted cancer therapy induces APOBEC-mediated mutagenesis, promoting drug resistance by increasing genetic diversity through mechanisms involving NF-κB activation and reduced DNA repair.

E-cadherin represses anchorage-independent growth in sarcomas through both signaling and mechanical mechanisms

This study identifies E-cadherin's role in suppressing sarcoma growth through both signaling (inhibiting p-CREB and TBX2) and mechanical (enhancing cell-cell adhesion) mechanisms.